Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05694741 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT05694741 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 31 participants.
The verdict
NCT05694741, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This study will assess the safety, tolerability, and pharmacokinetics of AZD0186 following single ascending doses (SAD) via oral administration in healthy adult participants.
Interventions
- DRUG Placebo
- DRUG AZD0186
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2022-12-20 |
| Est. Completion | 2023-05-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05694741
The ClinicalTrials.gov registry entry for NCT05694741 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05694741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05694741 about?
NCT05694741 is a clinical study titled "A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186". This study will assess the safety, tolerability, and pharmacokinetics of AZD0186 following single ascending doses (SAD) via oral administration in healthy adult participants.
What is the current status of trial NCT05694741?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2022-12-20. Estimated completion is 2023-05-10.
What interventions are being tested in trial NCT05694741?
The interventions under investigation include: Placebo (DRUG), AZD0186 (DRUG).
Who is sponsoring clinical trial NCT05694741?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.